392 reports of this reaction
2.7% of all ELACESTRANT reports
#8 most reported adverse reaction
CONSTIPATION is the #8 most commonly reported adverse reaction for ELACESTRANT, manufactured by Stemline Therapeutics, Inc.. There are 392 FDA adverse event reports linking ELACESTRANT to CONSTIPATION. This represents approximately 2.7% of all 14,750 adverse event reports for this drug.
Patients taking ELACESTRANT who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is a less commonly reported adverse event for ELACESTRANT, but still significant enough to appear in the safety profile.
In addition to constipation, the following adverse reactions have been reported for ELACESTRANT:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 392 FDA reports for ELACESTRANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 2.7% of all adverse event reports for ELACESTRANT, making it a notable side effect.
If you experience constipation while taking ELACESTRANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.